Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
We use essential cookies by default: sign-in, your choice in this banner (supstack-consent) and your language (NEXT_LOCALE). Vercel Web Analytics (cookieless page counts) and Sentry error reports (without replay) run either way. Only if you choose "Accept all" do we also create a browser ID in local storage (it ties your visits together in our site records), record error-replay diagnostics (Sentry: masked DOM snapshots, only when an error fires) and turn on load-time metrics (Vercel Speed Insights) so we can fix slow pages faster. Learn more about cookies
L-Methionine doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1975–2026 with a typical study size of 140 participants.
Based on 59 studies · 15 meta-analyses · 30 RCTs · 9,418 total participants
Study base
59 studies indexed
By outcome
Every outcome below: Too few graded studies.
Therapeutic & clinical19 studies
19 studies
Depression & mood17 studies
17 studies
Methylation & amino-acid metabolism16 studies
16 studies
Women's health6 studies
6 studies
Glucose & metabolic4 studies
4 studies
Liver health3 studies
3 studies
Cognitive function3 studies
3 studies
Inflammation3 studies
3 studies
Safety profile3 studies
3 studies
Heart & blood pressure2 studies
2 studies
Anxiety & stress1 study
1 study
Pain & analgesia1 study
1 study
Immune support1 study
1 study
By the numbers
Pulled from 18 studies with measurable effects
Likely real effects
50%
across studies
People studied
9,418
typical study: 140 people
Strongest designs
45
15 pooled, 30 randomised
How long studies ran
1–3 months
2
3+ months
2
Populations Studied
Patients with depression2
Patients with chronic liver disease1
MDD patients1
general population1
Active research area
28 studies in the last 5 years · Latest meta-analysis: 2026
197520002026
1Depression symptoms reliefMeta-AnalysisCited 10×n=1,522 · large study2024
In plain English: SAMe may provide relief of depression symptoms similar to imipramine or escitalopram.
Peng TR et al. · General hospital psychiatry (2024)
SAMe may provide relief of depression symptoms similar to imipramine or escitalopram.
However, the results of the comparisons should be interpreted with caution due to the small number of studies and the large range of SAMe doses that were used in the included trials.
Therefore, we recommend that patients discuss treatment options with their doctor before taking SAMe.
2Treatment of chronic liver diseaseMeta-AnalysisCited 44×n=705 · large study2015
In plain English: However, SAMe also demonstrated limited clinical value in the treatment of certain chronic liver diseases.
Guo T et al. · PloS one (2015)
In a subgroup analysis of gravidas and children, several of the included data indicated that there was a significant difference in the pruritus score.
Furthermore, the results regarding ursodeoxycholic acid (UDCA) and stronger neo-minophagen C (SNMC) indicated that both treatments were more effective than SAMe was in certain chronic liver diseases.
These findings suggest that SAMe could be used as the basis of a medication regimen for liver function improvement because of its safety.
5Peripheral blood metabolites in major depressive disorderMeta-AnalysisCited 183×2021
In plain English: MDD patients were characterized by higher levels of asymmetric dimethylarginine, tyramine, 2-hydroxybutyric acid, phosphatidylcholine (32:1), and taurochenodesoxycholic acid and lower levels of L-acetylcarnitine, creatinine, L-asparagine, L-glutamine, linoleic acid, pyruvic acid, palmitoleic acid, L-serine, oleic acid, myo-inositol, dodecanoic acid, L-methionine, hypoxanthine, palmitic acid, L-tryptophan, kynurenic acid, taurine, and 25-hydroxyvitamin D compared with controls.
Pu J et al. · Molecular psychiatry (2021)
Meta-analysis of peripheral blood metabolites from 46 studies comparing people with major depressive disorder and controls.
23 metabolites differed, and L-methionine was among those lower in people with depression, alongside L-tryptophan, kynurenic acid and taurine.
L-tryptophan and kynurenic acid were consistently lower regardless of antidepressant use. The study measures blood levels and does not test methionine supplementation.
6Depressive symptomsMeta-AnalysisCited 7×n=2,183 · very large study2024
In plain English: Moderate-certainty evidence suggests that SAMe monotherapy may offer a moderate therapeutic benefit in alleviating depressive symptoms.
Limveeraprajak N et al. · Progress in neuro-psychopharmacology & biological psychiatry (2024)
Our analysis included 23 trials (N = 2183) classified into three categories: 11 trials comparing SAMe and placebo, 5 trials comparing SAMe plus ADs and placebo plus ADs, and 7 trials comparing SAMe and ADs.
Differences between experimental and control interventions in reducing depressive symptoms were observed: i) SAMe demonstrated significantly superior efficacy compared to placebo (SMD = -0.58, 95% CI = -0.93 to -0.23, I2 = 68%); ii) in conjunction with ADs, SAMe did not show a significant difference from placebo (SMD = -0.22, 95%CI = -0.63 to 0.19, I2 = 76%); and iii) SAMe did not exhibit a significant difference from ADs alone (SMD = 0.06, 95%CI = -0.06 to 0.18, I2 = 49%).
No significant differences in dropout rates were observed across the three comparison categories.
In plain English: S-adenosylmethionine holds promise as a treatment for multiple neuropsychiatric conditions, but the body of evidence has limitations.
Sharma A et al. · The Journal of clinical psychiatry (2017)
Systematic review of 132 studies of SAMe for neuropsychiatric and comorbid medical conditions, 115 of them clinical trials.
It found promising but limited evidence of efficacy and safety for SAMe in major depressive disorder, as monotherapy and as an add-on to antidepressants.
The review covers SAMe, not L-methionine, and preliminary evidence in other disorders is described as limited.
In plain English: No recommendations were made when the evidence was low quality or trade-offs were so closely balanced that any recommendation would be too speculative.
Crawford C et al. · Pain medicine (Malden, Mass.) (2019)
No recommendations were made when the evidence was low quality or trade-offs were so closely balanced that any recommendation would be too speculative.
Research recommendations are provided to enhance the quality and body of evidence for the most promising ingredients.
Clinicians and those with chronic pain can rely on evidence-based recommendations to inform their decisions.
In plain English: However, there is currently a paucity of high-quality data regarding the use of add-on treatments in patients with MDD who are inadequate responders to antidepressants, with quetiapine XR presenting the most comprehensive evidence base to date.
Turner P et al. · Journal of psychopharmacology (Oxford, England) (2014)
Comparison of the different drug classes indicated that most interventions had similar efficacy.
The likelihood of response was significantly greater with SAMe versus placebo and lithium and with quetiapine XR versus placebo.
Most add-on interventions demonstrated comparable efficacy in patients with MDD and an inadequate response to initial antidepressants.
In plain English: Currently the scientific evidence is insufficiently robust to establish definitive clinical practice guidelines, but processes could be established to track the impact of these ingredients.
Crawford C et al. · Pain medicine (Malden, Mass.) (2019)
Evidence review and consensus recommendations on 19 dietary ingredients for chronic musculoskeletal pain in military personnel, graded with GRADE.
No recommendation was made for S-adenosyl-L-methionine, and eight ingredients, including avocado soybean unsaponifiables, curcuma, glucosamine and vitamin D, were conditionally recommended.
The panel judged the evidence not strong enough for definitive clinical practice guidelines.
13Systematic ReviewCited 6×n=14 · very small study2021
In plain English: The methodological shortcoming of existing studies and directions for future research are discussed to facilitate high-quality research in this evolving area of nutritional psychiatry.
Qureshi FM et al. · Aggressive behavior (2021)
Out of the 14 studies, 5 reported a beneficial effect of nutritional supplementation (omega-3 fatty acids, vitamins/minerals, S-adenosyl-l-methionine, or tryptophan).
The results overall indicated that research in this area is in its infancy: very few studies examined the same composition of nutritional supplementation and when they did so the results were contradictory.
The methodological shortcoming of existing studies and directions for future research are discussed to facilitate high-quality research in this evolving area of nutritional psychiatry.
In plain English: PA interventions may modulate maternal methionine and tCys concentrations, and our results suggest that maternal taurine status is linked to offspring birth weight, highlighting the potential of PA to influence key nutrients required for fetal development.
Jensen IKB, Roland CB, Trammell SAJ, Knudsen SP, Jessen AD, Bendix JM, Molsted S, Grevengoed TJ, Stallknecht BM, Løkkegaard E, Mortensen OH. · Nutrients (2026)
Results: Longitudinally, maternal methionine and taurine concentrations decreased significantly ( p < 0.001 for both) during pregnancy, while total cysteine (tCys) concentrations increased ( p < 0.001).
At GA 28+0-6 weeks, methionine concentrations were significantly higher in EXE ( p = 0.031) and MOT ( p = 0.006) groups compared to CON, and tCys was higher in the MOT group ( p = 0.017) versus CON.
Maternal taurine was positively associated with birth weight ( p = 0.034) and birth weight/placental weight ratio ( p = 0.010), while maternal tCys was negatively associated with head circumference ( p < 0.001).
Du H, Hu Y, Ye H, Di S, Yan H. · Frontiers in endocrinology (2026)
Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were synthesized using a random-effects model accounting for the potential influence of heterogeneity.
Overall, HHcy was significantly associated with uRPL (OR 3.46, 95% CI 2.33-5.14; I² = 57%).
The association was stronger in studies with Hcy cutoff > 12 μmol/L compared to ≤ 12 μmol/L (OR 4.02 vs. 2.00; p = 0.02), and in studies using HPLC or immunoassay compared with enzymatic methods (OR 3.59 and 4.53 vs. 1.84; p = 0.02).
Castagna A, Cotroneo AM, Mosele M, Sapone P, Martinelli E, Rahmati M, Smith L, Veronese N. · Aging clinical and experimental research (2026)
Eighty-three percent of outcomes showed significant associations with hyperhomocysteinemia.
Most meta-analyses were of low or critically low methodological quality.
Conclusions Across nearly one million participants, hyperhomocysteinemia was consistently associated with adverse health outcomes, particularly vascular, neurological, skeletal, and renal conditions.
In plain English: Participants in CAM trials were more likely to be female and to have a lower placebo-response rate compared to those in standard antidepressant trials for MDD.
Freeman MP et al. · The Journal of clinical psychiatry (2010)
Meta-analysis of 185 placebo-controlled RCTs in major depressive disorder, comparing standard antidepressants with St John's wort, omega-3 fatty acids and SAMe.
Both antidepressants and these complementary treatments beat placebo on response rates, and placebo response was lower in the complementary medicine trials (P = .002).
Discontinuation due to adverse events was higher in antidepressant trials than in complementary medicine trials. SAMe is not reported separately in the abstract.
19Antioxidant treatment effectiveness for ALSSystematic ReviewCited 66×n=23 · very small study2008
In plain English: While there is no substantial clinical trial evidence to support their clinical use, there is no clear contraindication.
Orrell RW et al. · Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases (2008)
Further well-designed trials of medications such as vitamin C and E are unlikely to be performed.
If future trials of antioxidant medications are performed, careful attention should be given to sample size, outcome measures, and duration of the trial.
The high tolerance and safety, and relatively low cost of vitamins C and E, and other considerations related to the lack of other effective treatments for amyotrophic lateral sclerosis, explain the continuing use of these vitamins by physicians and people with amyotrophic lateral sclerosis.
20Subclinical depression symptomsRCTCited 1×n=140 · medium study2023
In plain English: The received results confirm the available evidence for the properties of SAMe in depression and complement them with evidence of the ef-fectiveness of the Deprilium® complex that contains SAMe and L-methylfolate with methylcobalamin, which together produce pharmacological and clinical synergy to reduce the severity of subclinical depressive manifestations in patients with NCD.
Results: After 60 days a statistically significant difference was observed in all clinical indicators between the intervention group and the control group.
When comparing the indicators of the intervention group on the 1st and on the 60th day of the study, statistically significant changes (p <0.000) were observed in all three indicators.
Further studies of the effectiveness of the use of the Deprilium® complex in patients with NCD are required.